Canaan Partners X’s NextCure NXTC Stock Holding History

Canaan Partners X’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26,804	Closed	-$2.17M	–	5
2021 Q3	$2.17M	Sell	26,804 -43,066	-62%	-$3.78M	0.62%	4
2021 Q2	$6.73M	Hold	69,870	–	–	10.11%	2
2021 Q1	$8.39M	Hold	69,870	–	–	11.44%	2
2020 Q4	$9.14M	Sell	69,870 -72,756	-51%	-$9.4M	19%	2
2020 Q3	$15.1M	Sell	142,626 -26,411	-16%	-$3.25M	29.94%	2
2020 Q2	$43.5M	Hold	169,037	–	–	52.17%	1
2020 Q1	$75.2M	Sell	169,037 -18,833	-10%	-$10.1M	82.76%	1
2019 Q4	$127M	Buy	+187,870	New	+$94.2M	82.06%	1

Other funds holding NXTC

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $3.14B AUM 46.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Canaan Partners X's NXTC Position: Q4 2021 in Review

Canaan Partners X sold out of NextCure (NXTC) in Q4 2021, closing a stake of 26,804 shares — an estimated $2.17M sold.

Canaan Partners X first reported a position in NXTC in Q4 2019 and held it in 8 quarters. The position peaked at $127M in Q4 2019. 71 funds tracked by Wall St. Rank hold NXTC as of Q4 2021.

Canaan Partners X reported no remaining NextCure position as of Q4 2021 after selling out during the quarter.
Canaan Partners X sold 26,804 NextCure shares in Q4 2021, an estimated $2.17M.
Canaan Partners X first reported a position in NextCure in Q4 2019 and held it in 8 quarters.
Canaan Partners X's NextCure position peaked at $127M in Q4 2019.
71 funds tracked by Wall St. Rank held NextCure as of Q4 2021.

Based on Canaan Partners X's 13F filing for Q4 2021, filed 3 Feb 2022.